-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

907.P1.101 907. Outcomes Research: Plasma Cell Disorders: Poster I

Symposia: Outcomes Research: Plasma Cell Disorders Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, Combination therapy, Clinical trials, Adult, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Lymphomas, Epidemiology, Elderly, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, Clinical Research, Health outcomes research, Diversity, Equity, and Inclusion (DEI), Health disparities research, Supportive Care, Diseases, SARS-CoV-2/COVID-19, Therapy sequence, Patient-reported outcomes, Treatment Considerations, Infectious Diseases, Biological therapies, Real-world evidence, Adverse Events, Lymphoid Malignancies, Registries, Biological Processes, Myeloid Malignancies, Monoclonal Antibody Therapy, Technology and Procedures, Study Population, Profiling, Human, Pathogenesis
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)

Jiri Minarik1, Luděk Pour, MD2*, Tomas Jelinek3, Ivan Spicka, CSc4*, Alexandra Jungova5*, Jakub Radocha, MD, PhD6, Petr Pavlicek7*, Tomas Pika8*, Stork Martin9*, Jan Straub10*, Vojtech Latal11*, Dominik Fric2*, Vladimir Maisnar, MD, PhD6* and Roman Hajek, MD, PhD12

1Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic, Olomouc, Czech Republic
2Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic
3Department of Hematooncology, University Hospital Ostrava, Ostrava, Ostrava-Mesto, Czech Republic
41st Medical Department – Clinical Department of Haematology of the First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Prague, Czech Republic
5Hematology and Oncology Department, Charles University Hospital Pilsen, Pilsen, Czech Republic
64th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic
73rd Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Department of Internal Medicine and Hematology, Prague, Czech Republic
8Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
9Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
101st Medical Department – Clinical Department of Haematology, First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic
11University Hospital and Palacky University Olomouc, Olomouc, CZE
12University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic

Andrew J. Cowan, MD1, Luuk Gras2*, Hiroyuki Takamatsu, MD, PhD3,4, Linda Koster5*, Laurien Baaij III6*, Nada Hamad, MBBS, MSc, BSc7, Anita D'Souza, MD8, Noel Estrada-Merly, MS9*, Parameswaran N. Hari, MD, MBBS10, Wael Saber, MD, MS11, Minako Iida, MD, PhD12*, Shinichiro Okamoto13*, Shohei Mizuno, MD, PhD14*, Koji Kawamura, MD, PhD15*, Yoshihisa Kodera, MD16*, Bor-Sheng Ko, M.D. Ph.D.17, Christopher Liam, MRCP18*, KIM Wah HO, MBBS, MRCP19*, A Sim Goh, MD20*, S Keat Tan21*, Alaa M. Elhaddad, MD22, Ali Bazarbachi, MD, PhD23, Brig Qamar Un N Chaudhry, MBBS, FCPS24*, Rozan Alfar, MBBS25*, Mohamed Amine Bekadja26*, Malek Benakli, MD27*, Cristobal Augusto Frutos Ortiz, MD28*, Eloisa Riva, MD, MEd29, Sebastian Galeano, MD30, Francisca Bass, MD31*, Hira Mian, MD32, Arleigh McCurdy, MD33, Feng-Rong Wang, MD34*, Meng Lv, MD, PhD35, Daniel Neumann36*, Mickey Boon Chai Koh, MD, PhD37*, John Snowden, MD38*, Stefan Schonland39*, Donal P McLornan, MD, PhD40*, Patrick John Hayden, MD41, Rafael De La Camara, MD42, Raffaella Greco, MD43*, Fabio Ciceri, MD44*, Mette D. Hazenberg, MD, PhD45*, Anna Sureda Balari, MD, PhD46, Damiano Rondelli, MD47*, Hildegard T. Greinix, MD48, Mahmoud Aljurf49*, Yoshiko Atsuta50*, Dietger W. Niederwieser, MD51 and Laurent Garderet52*

1Fred Hutchinson Cancer Center, Seattle, WA
2EBMT, Leiden, Netherlands
3Department of Hematology, Kanazawa University, Kanazawa, Japan
4Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA
5EBMT Leiden Study Unit, Leiden, Netherlands
6EBMT Leiden Study Unit, Leiden, the Netherlands;, Leiden, Netherlands
7St Vincent's Hospital, Sydney, NSW, Australia
8Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
9BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
10The Medical College of Wisconsin, Brookfield, WI
11Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
12Aichi Medical University School of Medicine, Nagakute-cho, Aichi, JPN
13Keio University School of Medicine, Tokyo, JPN
14Division of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, AIC, Japan
15Division of Hematology and Clinical Laboratory Medicine, Tottori University Hospital, Yonago, Japan
16Aichi Medical University, Nagakute, AIC, JPN
17Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
18Hospital Sultanah Aminah, Johor Bahru, Malaysia
19Hospital Ampang, Ampang, Malaysia
20Penang General Hospital, Penang, Malaysia
21Hospital Pulau Pinang, Pulau Pinang, Malaysia
22Children Cancer Hospital Egypt - 57357, Cairo, Egypt
23American University of Beirut Dept. of Medicine, Beirut, Lebanon
24Pathwel center of Hematology and BMT, Rawalpindi, PAK
25Princess Margaret Hospital, Toronto, ON, CAN
26EHU, Oran, Algeria
27Pierre and Marie Curie Center, Algiers, Algeria
28Hospital Central Del Instituto De Prevision Social, Asuncion, Paraguay
29Hematology, Hospital de Clinicas, Montevideo, Uruguay
30Bone marrow transplant unit, British Hospital, Montevideo, Montevideo, Uruguay
31Intensive Hematology Unit, Hospital Del Salvador, Santiago, Chile
32McMaster University, Hamilton, ON, Canada
33The Ottawa Hospital, Ottawa, ON, Canada
34Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, CHN
35Peking University People's Hospital, Beijing, China
36Leipzig University, Leipzig, DEU
37St George's University Hospitals, London, United Kingdom
38Sheffield Blood & Marrow Transplant and Cellular Therapy Programme, Sheffield, United Kingdom
39Medical Department V, Amyloidosis Center, University of Heidelberg, Heidelberg, Germany
40Department of Haematology, University College London Hospitals NHS Trust, London, ENG, United Kingdom
41Department of Haematology, Trinity College Dublin, St. James’s Hospital, Dublin, Ireland
42Hospital Universitario de la Princesa, Madrid, Spain
43Unit of Hematology and Stem Cell Transplantation, IRCCS San Raffaele Scientific Institute, Milan, Italy
44Hematology and Bone Marrow Transplantation Unit, I.R.C.C.S. San Raffaele Scientific Institute, Milan, Italy
45Department of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands
46Hematology Department, Institut Català d’Oncologia - Hospitalet, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Spain
47Division of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
48Division of Hematology, Medical University of Graz, Graz, Austria
49Department of Hematology, Stem Cell Transplantation, and Cellular Therapy, Cancer Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
50The Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan
51Universitaetsklinikum Leipzig Aor, Leipzig, Germany
52Hematology, Pitie-Salpetriere Hospital, Greater Paris University Hospitals (AP-HP), Paris, France

Hua Xue1*, Jianmei Xu1*, Jing Wang1*, Songying Zhao1*, Huimei Guo1*, Jiangbo Zhang1*, Jia Liu1* and Yao Liu2

1Affiliated Hospital of Hebei University, Baoding, China
2Chongqing University Cancer Hospital, Chongqing, China

Sikander Ailawadhi1, Sarah M. Larson, MD2, Shannon Ferrante3*, Nicole Rafalko4,5*, Niodita Gupta-Werner5*, Jennifer S. Harper, PhD3*, Rohan Medhekar5*, Marjohn Armoon, PharmD6*, Annelore Cortoos, MD7*, Shuchita Kaila5 and Shebli Atrash, MD, MS8

1Division of Hematology-Oncology, Mayo Clinic-Florida, Jacksonville, FL
2UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA
3Janssen Scientific Affairs, LLC, Titusville, NJ
4Department of Epidemiology and Biostatistics, Drexel University Dornsife School of Public Health, Philadelphia, PA
5Janssen Scientific Affairs, LLC, Horsham, PA
6Medical Director, Multiple Myeloma, Hematology US Medical Affairs, Johnson & Johnson, Horsham, PA
7Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA
8Levine Cancer Institute, Charlotte, NC

James A Davis, PharmD1*, Jordan Snyder, PharmD2*, Mikhaila Rice, PharmD3*, Donald C Moore, PharmD, BCPS, BCOP, DPLA, FCCP4*, Christopher Cahoon, PharmD5*, Kelley Julian, PharmD6*, Charlotte B Wagner, PharmD7*, Katelynn Granger, PharmD8*, Kimberly M Green, DO1*, Shebli Atrash, MD9, Hailey Hill, PharmD9*, Jessica McElwee, PharmD9*, Grace Elsey, PharmD9*, Jack Khouri, MD10, Joslyn Rudoni, PharmD3*, Zahra Mahmoudjafari, PharmD11* and Victoria Nachar, PharmD12*

1Division of Hematology-Oncology, Medical University of South Carolina, Charleston, SC
2Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Overland Park, KS
3Department of Pharmacy, Cleveland Clinic, Cleveland, OH
4Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC
5Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
6University of Utah Huntsman Cancer Institute, Salt Lake City, UT
7Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
8Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
9Levine Cancer Institute, Charlotte, NC
10Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
11Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
12Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI

Oya Gilbert1*, Jack Aiello2*, Jim Omel3*, Pamela Price4*, Audrey Davis5*, Laura Ortiz-Ravick6*, Emily Gentry7*, Richa Shah8*, Elpitha Soussou8* and Brandon Blue, MD9

1Patient author, Studio City, CA
2In memoriam, Patient author, Southwest Oncology Group, San Jose, CA
3Patient author, Grand Island, NE
4Balm in Gilead, Richmond, VA
5Cancer Support Community, Washington, DC
6The Leukemia & Lymphoma Society, Rye Brook, NY
7Sarah Cannon at HCA Healthcare, Nashville, TN
8Pfizer Inc, New York City, NY
9H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Jaime Miller, MD1*, Mark Walker, PhD2*, Dmytro Assonov, MD, PhD3*, Leena Chhun, BS, BA1*, Kati O'Brien, BA4* and C. Anthony Blau, MD1

1All4Cure, Seattle, WA
2Walker Research Consulting, Germantown, TN
3Dmytro Assonov Consulting, Kyiv, Ukraine
4All4Cure, Tacoma, WA

Betty Gration, BMBCh, MRCP, BSc, M.Bioch1*, Cameron Wellard, BSc (Hons), PhD2*, Elizabeth Moore, PhD, MPH, PgradDip (Nurs Crit Care)2*, Marianne Tan, MBChB3, Matthew Murphy4*, Kenneth J C Lim, MBBS5, James Rowland6*, Nada Hamad, MBBS, MSc, BSc1, Rajeev Rajagopal, MD, MBBS3*, Peter Mollee, FRACP, MBBS, MSc, FRCPA7, Andrew Spencer, MBBS, DM (Lond), FRACP, FRCPA8,9*, Hang Quach, MD, FRACP, FRCPA, MBBS10 and Georgia McCaughan, BMedSc MBBS MMed (Clin Epi) FRACP FRCPA1*

1Haematology Department, The Kinghorn Cancer Centre, St Vincent's Hospital, Darlinghurst, NSW, Australia
2School of Public Health and Preventative Medicine, Monash University, Melbourne, VIC, Australia
3Middlemore Hospital, Auckland, NZL
4Haematology, The Alfred Hospital, Melbourne, Australia
5Hematology, St Vincent's Hospital Melbourne, Brunswick, Australia
6Princess Alexandra Hospital, Brisbane, AUS
7Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia
8Department of Malignant Haematology, Transplantation and Cellular Therapy Services, Alfred Health, Melbourne, Australia
9Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
10St. Vincent's Hospital Melbourne, East Melbourne, Australia

Arshi Syal, MD1,2, Yajur Arya, MD1,2, Bruce Adrian Casipit, MD1,2*, Claudia Dourado, MD1,2 and John Charles Leighton, MD1,2*

1Albert Einstein Medical Center, Philadelphia, PA
2Thomas Jefferson University Hospital, Philadelphia, PA

Victoria Badia, MD1*, Apoorva Doshi, MBBS2*, Gayathri Ravi, MD1, Susan Bal, MD1, Kelly Godby1*, Donna Murdaugh, PhD2*, Luciano J. Costa, MD, PhD3, Grant Williams, MD1*, Smita Bhatia, MD, MPH2 and Smith Giri, MD, MS1*

1Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
2Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL
3Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Vestavia, AL

Markus Rückert1*, Guillaume Azarias1*, Mamta Garg, MD2*, Ceri Bygrave, MBBCh MRCP FRCPath3*, Hannah Belcher, BN3*, Clare Hague4*, Kristina Bardenheuer5*, Wout Vekemans6*, Morten Salomo7*, Blanca Gros Otero8*, Nolen Perualila6*, Michel Van Speybroeck6*, Joris Diels6*, Vladimir Maisnar, MD, PhD9*, Ivan Špička10* and Roman Hájek11

1TriNetX Oncology GmbH, Freiburg, Germany
2University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
3Cardiff and Vale University, Cardiff, Wales, United Kingdom
4Janssen-Cilag GmbH, Neuss, Germany
5Oncology Access Solutions Ltd, Macclesfield, United Kingdom
6Janssen Pharmaceutica NV, Beerse, Belgium
7Janssen-Cilag, Birkerod, Denmark
8Janssen-Cilag, Madrid, Spain
9Charles University Hospital, Hradec Králové, Czech Republic
10Charles University Hospital, Prague, Czech Republic
11University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic

Andrew Kowalski, PharmD1*, David G. Coffey, MD2, Benjamin Diamond, MD2, James E. Hoffman2, Marcella Kaddoura, MD3, Jill Lykon, PharmD2*, Francesco Maura, MD4, Yahirini Rodriguez-Martinez, APRN2*, Suzan Rosen, APRN2*, Faika Shah, APRN2*, Dennis Verducci, APRN2*, Ola Landgren5 and Dickran Kazandjian, MD2

1Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Coral Gables, FL
2Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
3Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Dearborn, MI
4University of Miami, Coral Gables, FL
5Sylvester Comprehensive Cancer Center, Miami, FL

Daniel Thomas Jones, OMS-IV1*, Hazem Aboaid, MD2, Ramaditya Srinivasmurthy, OMS-IV1*, Kevin Nguyen, OMS-IV1*, Rishi Kumar Nanda, OMS-III1*, Kyaw Zin Thein, MD3 and Thura Win Htut, MBBS, MRCP, FRCPath4*

1Touro University Nevada College of Osteopathic Medicine, Las Vegas
2Department of Internal Medicine, Kirk Kerkorian School of Medicine at University of Nevada, Las Vegas, Las Vegas, NV
3Division of hematology and medical oncology, Comprehensive Cancer Centers of Nevada, Central Valley, Las Vegas, NV
4Department of Haematology, Aberdeen Royal Infimary, Aberdeen, United Kingdom

Amy E. Pierre, MSN1*, Gene Ho, MPH2*, Olive Mbah, PhD, MHS3*, Jingru Wang, BA3* and Cleo A. Ryals, PhD3*

1Flatiron Health, River Vale, NJ
2Flatiron Health, San Francisco, CA
3Flatiron Health, New York, NY

Rahul Banerjee, MD, FACP1, Ruibin Wang, PhD2*, Yi-Hsuan Liu, PhD, MS, RD2*, Jinghua He2*, Hoa H. Le, PhD2*, Saurabh N. Patel, MD2* and Xinke Zhang, PhD2*

1Fred Hutchinson Cancer Center, Seattle, WA
2Johnson & Johnson Innovative Medicine, Horsham, PA

William A. Wood, MD, MPH1, Emily A. Semmel, MS2*, Shandra James2*, Donna S. Neuberg, ScD3, Kathleen Hewitt, DNP, RN4*, Kenneth C. Anderson, MD5, Shaji Kumar, MD6, Mark A. Schroeder, MD7, David J. Chung, MD, PhD8, Aaron S. Rosenberg, MD9, Jeffrey A. Zonder, MD 10, Samuel M. Rubinstein, MD11, Anita D'Souza, MD12, Thomas Martin, MD13, Ajai Chari, MD14, Ravi Vij, MD, MBA7, Ajay K. Nooka, MD, MPH15, Brendan M. Weiss, MD16, Levi D. Pederson, MS17*, Andriy Derkach, PhD18*, Susan M. Geyer, PhD19 and Saad Z. Usmani, MD20

1Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
2ASH Research Collaborative, Washington, DC
3Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
4ASH Research Collaborative, Gainesville, VA
5Dana-Farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
6Division of Hematology, Mayo Clinic, Rochester, MN
7Division of Oncology, Washington University School of Medicine, St. Louis, MO
8Transplant and Cellular Therapy Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
9UC Davis Comprehensive Cancer Center, Sacramento, CA
10Karmanos Cancer Institute, Detroit, MI
11Division of Hematology, University of North Carolina School of Medicine, Chapel Hill, NC
12Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
13Department of Hematology, University of California at San Francisco, San Francisco, CA
14University of California, San Francisco, San Francisco, CA
15Winship Cancer Institute of Emory University, Atlanta
16Moderna, Inc., Cambridge, MA
17Mayo Clinic, Rochester, MN
18Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
19Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN
20Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Farheen Chunara1*, Mansi R. Shah, MD2, Nishi Shah, MBBS, MPH3, Jessica Kent1*, Ghulam Rehman Mohyuddin, MD4, Sabarinath V Radhakrishnan, MD1*, Gurbakhash Kaur, MD, MA5, Rajshekhar Chakraborty, MD6, Leo Rasche, MD7*, Carolina Schinke, MD8, Anita D'Souza, MD, MS9*, Aniko Szabo, PhD9* and Meera Mohan, MD10

1Medical college of Wisconsin, Milwaukee, WI
2Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
3Montefiore Einstein Comprehensive Cancer Center, Blood Cancer Institute, Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
4Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
5Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
6Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY
7Department of Internal Medicine, University Hospital of Würzburg, Würzburg, Germany
8Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR
9Medical College of Wisconsin, Milwaukee, WI
10Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Lucio Gordan1*, Amanda Warner1*, Hannah Granger, BSN1*, Amy Ming2*, Cindy Chen3*, Nicole Rafalko4,5*, Jennifer S. Harper, PhD3*, Niodita Gupta-Werner5*, Rohan Medhekar5*, Shuchita Kaila5, Annelore Cortoos, MD5* and Trevor Heritage1*

1Florida Cancer Specialists & Research Institute, Tampa, FL
2Florida Cancer Specialists & Research Institute, T, FL
3Janssen Scientific Affairs, LLC, Titusville, NJ
4Drexel University, Philadelphia, PA
5Janssen Scientific Affairs, LLC, Horsham, PA

Apoorva Doshi, MBBS1*, Abigail Tucker, MSPH2*, Clare Ubarsax, BS3*, Gayathri Ravi, MD4, Grant Williams, MD4* and Smith Giri, MD, MS4*

1Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL
2University of Alabama at Birmingham, Birmingham, AL
3University of Colorado School of Medicine, Aurora, CO
4Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL

Renee Cheng, MD1, Ariana Feuvrier-Rivera2*, Philip Yeung1*, Anupama Deepa Kumar, MD3 and Ayad Hamdan4*

1UCSD Moores Cancer Center, San Diego, CA
2University of California at San Diego Health, San Diego, CA
3University of California, San Francisco, San Francisco, CA
4UCSD Moores Cancer Center, La Jolla, CA

Timothy C. Beer, MD1*, Gloria HJ Graf, PhD2*, Dee Lin3*, Mariana Fernandez, MD4*, Margaret Doyle5, Laura L. Hester, PhD, MSc6*, Bingcao Wu3* and Stephen Huo, PhD, MD, MsPH2*

1Ann B. Barshinger Cancer Institute, Penn Medicine Lancaster General Health, Lancaster, PA
2Janssen Global Services, LLC, Raritan, NJ
3Janssen Scientific Affairs, LLC, Horsham, PA
4Janssen Cilag S.A., Madrid, Spain
5Janssen Global Services, Dublin, Ireland
6Janssen Research & Development, LLC, Raritan, NJ

Yonatan Lean, BSc1*, Andrew Yoon2*, Kristi Graves, PhD3*, Betina Yanez, PhD1*, Christine Rini, PhD4* and Jonathan Moreira, MD4

1Northwestern University Feinberg School of Medicine, Chicago, IL
2Northwestern University Feinberg School of Medicine, Hawthorn Woods, IL
3Georgetown University School of Medicine, Washington, DC
4Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL

Binoy Yohannan, MD1,2, Matthew James Rees, MD1, Morie A. Gertz, MD1, Angela Dispenzieri, MD1, Francis Buadi, MD1, David Dingli, MD, PhD1, Nelson Leung, MD3, Prashant Kapoor, MD4, Wilson I. Gonsalves, MD1, Taxiarchis Kourelis, MD1, Joselle Cook, MBBS1, Moritz Binder, MD1, Martha Lacy, MD1*, Suzanne R Hayman, MD1, Yi Lin, MD, PhD1, Yi Lisa Hwa, APRN, DNP, CNP1, Michelle G Rogers1*, Miriam Hobbs, APRN, CNP, DNP1*, Amie Fonder, PA-C, MS1*, Ronald S Go, M.D.1, Rahma M Warsame, MD1, Vincent Rajkumar, MD1*, Shaji Kumar, MD1 and Eli Muchtar, MD1

1Division of Hematology, Mayo Clinic, Rochester, MN
2Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
3Division of Nephrology, Hematology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
4Mayo Clinic, Rochester, MN

Luciano J. Costa, MD, PhD1, Thomas W. LeBlanc, MD, MA, MS2, Hans Tesch3*, Pieter Sonneveld, MD4, Sarasa M.A. Johnson5*, Francis Vekeman5*, Patrick Hlavacek6*, Aster Meche6*, Paul Cislo7*, David Hughes, PharmD8, Guido Nador9* and Marco DiBonaventura6*

1Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Vestavia, AL
2Duke Cancer Institute, Hillsborough, NC
3Bethanien Hospital, Frankfurt, Germany
4Erasmus MC Cancer Institute, Rotterdam, Zuid-Holland, Netherlands
5Statlog, Montreal, Canada
6Pfizer Inc, New York, NY
7Pfizer Inc, Groton, CT
8Pfizer, Cambridge, MA
9Pfizer Ltd, Surrey, United Kingdom

Bhavesh Mohan Lal, MD1, Alan Baltz, MD2*, Mamatha Gaddam, MD2, Ankur Varma, MD2, Cesar Giancarlo Gentille Sanchez, MD2 and Muthu V. Kumaran, MD2*

1University of Arkansas for Medical Sciences, Little Rock, Little Rock, AR
2University of Arkansas for Medical Sciences, Little Rock, AR

Blin Nicolas1*, Christine Mai, MD2*, Siegfried Ertl, MBA3*, Elodie Schneider, MBA2*, Marine Leberre, MBA2*, Melissa Yilmaz, MSc2* and Alexandre Raffy4*

1Hematology, Nantes University Hospital, Nantes, FRA
2AplusA, Lyon, France
3AplusA, London, United Kingdom
4APLUSA, Lyon, France

Darryl Chang, MD1,2, Alma Habib, MD2,3, Andrew Vegel, MD2,4*, Emily Struble, DNP2,4*, Hira Shaikh, MD2,4, Christopher Strouse, MD2,4, Kimberly M Green, DO2,5*, Muhammad Umair Mushtaq2,6, Zahra Mahmoudjafari, PharmD2,6*, Hamza Sloan Hashmi, MD7,8*, Joseph P. McGuirk, DO2,9, Abdullah Mohammad Khan, MD, MBBS2,3, Al-Ola Abdallah, MD2,9, Nausheen Ahmed, MD2,6, Shebli Atrash, MD, MS1,2 and Manisha Bhutani, MD1,2

1Levine Cancer Institute, Atrium Health, Charlotte, NC
2US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
3Division of Hematology, The Ohio State University, Columbus, OH
4Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA
5Division of Hematology-Oncology, Medical University of South Carolina, Charleston, SC
6Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
7Myeloma Service, Department of Medicine, Memorial Sloan Kettering, Charleston, SC
8US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, NY
9Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS

Bhavesh Mohan Lal, MD1, Toshali Pandey2*, Marah Alzubi3*, Jawad Alrawabdeh3*, John D Shaughnessy, Jr, PhD4*, Fenghuang Zhan, MD5, Eric Siegel6*, Carolina Schinke, MD5, Sharmilan Thanendrarajan, MD7, Maurizio Zangari, MD5, Frits van Rhee, MD, PhD5 and Samer Al Hadidi, MD, MSc7

1University of Arkansas for Medical Sciences, Little Rock, Little Rock, AR
2University of Arkansas for Medical Sciences, Little Rock
3University of Jordan, Amman, Jordan
4Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical sciences, Little Rock, AR
5Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR
6Department of Biostatistics, University of Arkansas For Medical Sciences, Little Rock, AR
7University of Arkansas for Medical Sciences, Little Rock, AR

Alvaro Alvarez Soto, MD1, Junmin Song, MD2, Jackson Clark, DO3, Katharine Hooper, FNP-BC1*, Maxine Amber Braun4*, Princy Shah, MD4* and Swarup Kumar, MBBS1

1Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut, Farmington, CT
2Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY
3University of Connecticut, Farmington
4University of Connecticut, Farmington, CT

Poorva Bindal, MD1, Marcela Banegas2*, Rodrigo Paredes3*, Maria Jose Hernandez Woodbine4*, Pushan Aggarwal5*, Jon E. Arnason, MD6 and Carolyn D Alonso, MD7*

1Division of Hematology/Oncology, Department of Medicine, UMass Chan Medical School, Grafton, MA
2Johns Hopkins Bloomberg School of Public Health, Baltimore
3Icahn School of Medicine at Mount Sinai Hospital, New York City, NY
4Norwalk Hospital/Yale University, Norwalk
5Allegheny Health, Pittsburg
6Beth Israel Deaconess Medical Center, Boston, MA
7Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Behzad Amoozgar, MD, MPH1, Ayrton I Bangolo, MBBS2, David H. Vesole, MD, PhD3,4, David S. Siegel, MD, PhD5, Noa Biran, MD3, Pooja Phull, MD3*, Michele L. Donato, MD6 and Harsh Parmar, MD3

1John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
2John Theurer Cancer Center at Hackensack University Medical Center, Edgewater, NJ
3Division of Multiple Myeloma, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
4Lombardi Comprehensive Cancer Center, Medstar Georgetown Medical Center, Washington, DC, DC
5Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack Meridian Health and Center for Discovery and Innovation, Hackensack, NJ
6Stem Cell Transplantation and Cellular Therapy Program, John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ

Michael Daunov, DO1, Benjamin Gorham, PhD2* and James J Ignatz-Hoover, MD, PhD3

1Department of Hematology and Stem Cell Transplant, University Hospitals Seidman Cancer Center, Cleveland, OH
2Freedman Center for Digital Scholarship, Kelvin Smith Library, Case Western Reserve University, Cleveland, OH
3Case Comprehensive Cancer Center, Cleveland Heights, OH

Lisa Herms, PhD*, Zhaohui Su, PhD*, Jessica Paulus, ScD* and Ira Zackon, MD

Ontada, Boston, MA

Xuezhu Xu1*, Rui Liu2*, Ruoyu Yang3*, Wanhong Zhao, PhD, MD4*, Baiyan Wang, MD, PhD4*, Fangxia Wang3* and Aili He, PhD, MD5*

1Department of Hematology, Xi'an Jiaotong University Second Affiliated Hospital,Xi'an Key Laboratory of Hematological Diseases, XI'AN, China
2Department of hematology, Xi'an Jiaotong University Second Affiliated Hospital,Xi'an Key Laboratory of Hematological Diseases, Xi'an, China
3Department of Hematology, Xi'an Jiaotong University Second Affiliated Hospital,Xi'an Key Laboratory of Hematological Diseases, Xi'an, China
4Department of Hematology, The Second Affiliated Hospital of Xi’an Jiao Tong University, Xi'an Key Laboratory of Hematological Diseases, Xi'an, China
5Department of Hematology, The Second Affiliated Hospital of Xi’an Jiao Tong University, Xi'an Key Laboratory of Hematological Diseases, Xi’an, China

Ishita Kamboj, BM1,2, Darryl Chang, MD3, Alma Habib, MD4, Andrew Vegel, MD5*, Emily Struble, DNP5*, Hira Shaikh, MD2,5*, Christopher Strouse, MD2,5, James A Davis, PharmD2,6*, Aliya Rashid, DO, MPH2,7,8, Kevin Graf, MD2,9*, Kimberly M Green, DO10*, Muhammad Umair Mushtaq, MD2,8, Zahra Mahmoudjafari, PharmD2,8*, Hamza Sloan Hashmi, MD11,12,13*, Joseph P. McGuirk, DO8, Al-Ola Abdallah, MD2,8, Shebli Atrash, MD2,14, Abdullah Mohammad Khan, MD, MBBS2,4 and Nausheen Ahmed, MD2,15

1Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, KANSAS CITY, MO
2US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
3Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC
4Division of Hematology, The Ohio State University, Columbus, OH
5Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA
6Department of Hematology-Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
7Internal Medicine, University of Kansas Medical Center, Kansas City, KS
8Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
9Department of Hematology-Oncology, Medical University of South Carolina, Charleston, SC
10Division of Hematology-Oncology, Medical University of South Carolina, Charleston, SC
11Myeloma Service, Department of Medicine, Memorial Sloan Kettering, Charleston, SC
12Department of Hematology-Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, NY
13US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, NY
14Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC
15University of Kansas Cancer Center, Kansas City, KS

Phyu Thin Naing, MD1, Divya Chukkalore, MD2*, Jessica Jung, BS3*, Clary Evans, MD, MA, MSc4* and Jessica Caro, MD5

1Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Uniondale, NY
2Zuckerberg Cancer Center, Northwell Health Cancer Institute, New Hyde Park, NY
3Northwell Health Cancer Institute, New Hyde Park, NY
4Radiation Oncology Department, Northwell Health Cancer Institute, New Hyde Park, NY
5Zuckerberg Cancer Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY

Rusha Bhandari, MD, MS1, Qingrui Meng, MS2*, Nora Balas, PhD3*, Alysia Bosworth, BA4*, F. Lennie Wong, PhD1, Wendy Landier, PhD2*, Liton Francisco5*, Elizabeth Ross3*, Ravi Bhatia, MD6, Smita Bhatia, MD, MPH3, Saro Armenian, DO, MPH4 and Lindsey Hageman, MPH5*

1City of Hope, Duarte, CA
2University of Alabama At Birmingham, Birmingham, AL
3University of Alabama at Birmingham, Birmingham, AL
4City of Hope National Medical Center, Duarte, CA
5Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL
6Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL

Mahmoud R. Gaballa, MD1, Thomas G. Martin, MD2, Nobuhiro Tsukada, MD, PhD3, Kazuhito Suzuki, MD, PhD4, Hirono Iriuchishima, MD, PhD5*, Emilie Chalayer, MD, PhD6*, Vincent Camus, MD, PhD7*, Maria Magdalena Alcala Peña8*, Anna Furlan, MD9*, Max Christian Georg Hubmann10*, Wolfgang Ulrich Knauf, MD11*, Christina Tekle12*, Ani Minasyan12*, Chunfu Qiu13* and Meral Beksac14,15*

1Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Hematology, University of California at San Francisco, San Francisco, CA
3Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
4Division of Clinical Oncology/ Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
5Department of Hematology, National Hospital Organization Shibukawa Medical Center, Gunma, Japan
6Department of Hematology, Centre Hospitalo Universitaire de Saint-Etienne, Saint Etienne, France
7Department of Hematology, Centre Henri Becquerel, Rouen, France
8Department of Hematology, Hospital Universitario Carlos Haya, Malaga, Spain
9Divisione di Ematologia, Ospedale Cà Foncello di Treviso-ASL 2, Treviso, Italy
10Praxis für Hämatologie und Onkologie, Herrsching, Germany
11Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany
12Sanofi, Cambridge, MA
13Sanofi, Cambridge
14Istinye University Ankara Liv Hospital, Ankara, Turkey
15Department of Hematology, Ankara University, Ankara, Turkey

Yoshiaki Marumo, MD1*, Masaki Ri, MD, PhD2,3*, Toru Ebina, MD4*, Tomoyuki Nakamura1*, Hirokazu Sasaki, MD2*, Shiori Kinoshita, MD, PhD2*, Tomoko Narita, MD, PhD2*, Tomotaka Suzuki2*, Takaomi Sanda, MD, PhD2, Takanori Nanri3*, Hirokazu Komatsu, MD, PhD2* and Shinsuke Iida, MD, PhD5

1Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, AIC, Japan
2Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
3Department of Blood Transfusion and Cell Therapy, Nagoya City University Hospital, Nagoya, Japan
4Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Aomori, Japan
5Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan

Jordan Snyder, PharmD1,2*, Kevin Graf, MD1,3*, James A Davis, PharmD1,4*, Marshall McKenna, MD1,5*, Yun Kyoung Tiger, MD, PhD1,5, Mehak M Laharwal, MD1,6, Prerna Mewawalla, MD1,7*, Omar Alkharabsheh, MD1,8*, Hamza Sloan Hashmi, MD9,10*, Hira Shaikh, MD1,11*, Jonathan Lochner, PharmD11*, Darryl Chang, MD1,12, Shebli Atrash, MD, MS1,12, Alma Habib, MD1,13, Priyanka Venkatesh, MBBS1,14, Zahra Mahmoudjafari, PharmD1,15*, Nausheen Ahmed, MD1,16, Muhammad Umair Mushtaq, MD1,2, Al-Ola Abdallah, MD1,15, Kimberly M Green, DO1,4* and Abdullah Mohammad Khan, MD, MBBS1,13

1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
2Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Overland Park, KS
3Department of Hematology-Oncology, Medical University of South Carolina, Charleston, SC
4Division of Hematology-Oncology, Medical University of South Carolina, Charleston, SC
5Division of Hematology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
6Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pitts, PA
7Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA
8University of South Alabama, Mobile, AL
9Myeloma Service, Department of Medicine, Memorial Sloan Kettering, Charleston, SC
10US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, NY
11Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA
12Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC
13Division of Hematology, The Ohio State University, Columbus, OH
14Internal Medicine, The University of Kansas Medical Center, Kansas City, KS
15Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
16University of Kansas Cancer Center, Kansas City, KS

*signifies non-member of ASH